Elicio Therapeutics raised roughly $15 million on July 1, 2026, through a registered direct offering to institutional investors. The company sold about 4.38 million common shares at $3.43 each, with Titan Partners Group and B. Riley Securities arranging the deal. Settlement lands on July 6, 2026, and the company agreed to a 30-day lock-up period restricting the issuance or sale of additional stock or stock equivalents immediately after closing.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding ELICIO THERAPEUTICS INC (ELTX)?

Major stakeholders currently include Knoll Capital Management, LLC ($6.7M), Vanguard Capital Management LLC ($5.5M), Susquehanna International Group, LLP ($4.0M). Based on the latest 13F filings, there are a total of 49 tracked investment funds and institutions maintaining positions in ELTX.

What is the overall institutional sentiment toward ELTX recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $14.1M, driven by 30 managers accumulating shares while 15 reduced their exposure.

Which institutions have been selling or reducing their ELTX positions?

In the latest period, 7 funds trimmed their holdings, and 8 managers completely exited their positions. The aggregate reported sell value was $4.3M.

Are there any notable investors adding ELTX to their portfolios?

Yes, buying activity remains notable. 16 institutions opened new positions in {ticker}, and 14 existing holders added to their shares. The total reported buy value for the quarter amounted to $17.5M.